Apitegromab helps tirzepatide users lose fat while preserving lean mass

https://www.news-medical.net/news/20260609/Apitegromab-helps-tirzepatide-users-lose-fat-while-preserving-lean-mass.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 A phase 2 trial suggests that blocking myostatin activation may help people taking tirzepatide retain more lean body mass without blunting weight loss. A recent phase II randomized clinical trial (RCT) published in the journal Nature Medicine showed that apitegromab, a monoclonal antibody, when administered along with tirzepatide, could help preserve lean body mass while supporting overall weight loss.